Filgrastim & Pegfilgrastim Biosimilars & Biosuperiors 2015 – a G-CSF & GM-CSF Competitor Analysis

  • ID: 3378008
  • Report
  • Region: Global
  • 76 Pages
  • La Merie Publishing
1 of 4
With 2014 Sales Of About US$ 6 bln, First And Next Generation G-CSF Products Represent An Attractive Market Size For Biosimilar Proteins In Regulated Markets
The Competitive Intelligence report Filgrastim & Pegfilgrastim Biosimilars & Biosuperiors 2015 – a G-CSF & GM-CSF Competitor Analysis describes product portfolios and R&D pipelines of granulocyte colony stimulating factor (G-CSF) and GM-CSF products and product candidates in regulated and in less regulated markets as of July 2015. Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

With 2014 sales of about US$ 6 bln, first and next generation G-CSF products represent an attractive market size for biosimilar proteins in regulated markets. Biosimilar filgrastim products have already been introduced into the the European Union and now are also entering the US market. Importantly, biosimilar products from Indian companies are among the approved products indicating that Indian companies can fulfill Western standards of cGMP manufacturing and cGCP development of at least relatively simple therapeutic proteins such as filgrastim.

The report includes a compilation of currently marketed branded and non-branded G-CSF and GM-CSF products in regulated and less regulated markets for treatment of chemotherapy-induced neutropenia. The report includes the market size of branded G-CSF products in 2014. In addition, the report lists company-specific product portfolios and R&D pipelines of G-CSF/GM-CSF products and projects. Competitor projects are listed in a tabular format providing information on:

- Drug Codes
- Target / Mechanism of Action
- Class of Compound
- Company
- Product Category
- Indication
- R&D Stage and
- additional comments with a hyperlink leading to the source of information
READ MORE
Note: Product cover images may vary from those shown
2 of 4
1. 2014 Sales of Branded Filgrastim, Lenograstim & Pegfilgrastim Products

2. Filgrastim & Lenograstim: Originator, Biosimilar & Biosuperior Products in EU

3. Filgrastim: Originator, Biosimilar & Biosuperior Products in USA

4. Filgrastim, Lenograstim & Nartograstim: Originator, Biosimilar & Biosuperior Products in Japan

5. Filgrastim: Biosimilar Products in India, Pakistan & Bangladesh

6. Filgrastim: Biosimilar Products in China & Taiwan

7. Filgrastim: Biosimilar Products in South Korea

8. Filgrastim & Lenograstim: Biosimilar Products in Latin America

9. Filgrastim: Biosimilar Products in Other Less Regulated Markets

10. Pegfilgrastim: Originator, Biosimilar & Biosuperior Products in EU

11. Pegfilgrastim: Originator, Biosimilar & Biosuperior Products in USA

12. Pegfilgrastim: Originator, Biosimilar & Biosuperior Products in Japan

13. Pegfilgrastim: Biosimilar Products in India & Pakistan

14. Pegfilgrastim: Biosimilar & Biosuperior Products in China & Taiwan

15. Pegfilgrastim: Biosimilar & Biosuperior Products in South Korea

16. Pegfilgrastim: Biosimilar Products in Other Less Regulated Markets

17. GM-CSF: Sargramostim Originator & Biosimilar Products worldwide

18. GM-CSF: Molgramostim Originator & Biosimilar Products worldwide

19. Corporate Filgrastim & Pegfilgrastim Biosimilar & Biosuperior Portfolios

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Question Does this country break sales figures down on a country by country basis?
Answer This report does not cover country-by-country revenue.
Question Does this country break sales figures down on a unit basis?
Answer This report does not cover unit sales figures.
Note: Product cover images may vary from those shown
Adroll
adroll